Conti Rena, Dusetzina Stacie B, Sachs Rachel
Rena Conti ( rconti@bu. edu ) is an associate professor in the Department of Markets, Public Policy, and Law at Boston University Questrom School of Business and associate research director of Biopharma and Public Policy for the Boston University Institute for Health System Innovation and Policy, in Massachusetts.
Stacie B. Dusetzina is an associate professor of health policy and the Ingram Associate Professor of Cancer Research at Vanderbilt University School of Medicine, in Nashville, Tennessee.
Health Aff (Millwood). 2020 Mar;39(3):445-452. doi: 10.1377/hlthaff.2019.01432.
The Affordable Care Act contained a range of provisions that altered prescription drug access and affordability for patients, payers, and providers. Yet the act stopped short of instituting systemic changes in the pricing of drugs, in part to address concerns that more fundamental changes might disrupt the development of new medicines. Looking back a decade after the Affordable Care Act became law, we found that new drug approvals have accelerated and the therapeutic advances embodied in some novel medicines are substantial-as are the prices that companies are charging for them. The lack of affordability of prescription drugs has become an increasing challenge for American patients and payers, particularly those with limited budgets. In this article we consider how things have changed in the past decade and how missed opportunities in the Affordable Care Act's passage figure prominently in the current drug pricing debate.
《平价医疗法案》包含一系列条款，这些条款改变了患者、支付方和医疗服务提供者获取处方药的途径以及药品的可负担性。然而，该法案并未对药品定价进行系统性变革，部分原因是为了应对这样的担忧：更根本性的变革可能会扰乱新药的研发。回顾《平价医疗法案》成为法律后的十年，我们发现新药获批速度加快，一些新型药物所体现的治疗进展颇为显著，而制药公司为这些药物设定的价格亦是如此。处方药难以负担的问题，对美国患者和支付方而言，尤其是那些预算有限的群体，已成为日益严峻的挑战。在本文中，我们将探讨过去十年情况如何变化，以及《平价医疗法案》在立法过程中错失的机会如何在当前的药品定价辩论中凸显出来。
